Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
On Thursday, 28 May, at 11 a.m. CEST, Mr. Chaubard will present “Allogeneic T-Cell Therapies: Shifting Towards Commercial Manufacturing,” which will discuss the approach that Catalent is adopting to scale-up and commercialize allogeneic cell therapies using its Manufacturing by Design (MbD) methodology. Developed in-house, this methodology is designed to solve the process efficiency and supply chain complexities and challenges associated with T-Cell manufacturing. He will also discuss the importance of establishing a specific and optimized fill and finish platform, and will speak to the combined cell and gene therapy capabilities at Catalent which position the company as a full-service global provider of advanced therapeutics.
Mr. Chaubard has 25 years’ experience in the biotechnology industry and has worked for a number of companies including GSK and Sanofi as well as Contract Manufacturing Organizations including CMC Biologics and Yposkesi. He joined Catalent in 2020 with the company’s acquisition of MaSTherCell, and has been involved in the development and scale-up of different industrial processes based on mammalian cell lines to produce recombinant proteins, vaccines, and viral vectors. His work has focused on the development and implementation of new technologies in the manufacture of advanced therapies.
For more information, please visit https://www.catalent.com/events/isct-2020/.
ABOUT CATALENT CELL & GENE THERAPY
Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, and with deep experience in viral vector scale-up and production. When Catalent recently acquired MaSTherCell, it added expertise in autologous and allogeneic cell therapy development and manufacturing to position Catalent as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has produced more than 100 cGMP batches across 70+ clinical and commercial programs.
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com